This study is testing secukinumab, a biological medicine given by injection under the skin, for its long-term safety. It's for people who have already been in a Novartis study with secukinumab, whose doctors believe they are still benefiting from the treatment, and who cannot get the medicine through regular means. The study aims to see how safe secukinumab is over time by tracking any side effects or serious side effects for up to two years. People aged 6 to 100 years old can join, regardless of gender. The current status of the study is unclear, and it plans to enroll about 1000 participants.

Study design

This is an open-label study, meaning both you and the study team will know you are receiving secukinumab. It plans to include about 1000 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The study will track side effects for up to two years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.